Converting patients from warfarin to non-vitamin K antagonist oral anticoagulants

被引:0
|
作者
Romanelli, Sarah [1 ,2 ]
Rivera, Veronica [1 ]
机构
[1] Mt Sinai Hosp, Martha Stewart Ctr Living, Brookdale Dept Geriatr & Palliat Med, New York, NY USA
[2] Mt Sinai Hosp, Martha Stewart Ctr Living, Brookdale Dept Geriatr & Palliat Med, 1468 Madison Ave,Annenberg Bldg 10th Floor Box 107, New York, NY 10029 USA
关键词
Anticoagulant; atrial fibrillation; geriatrics; primary health care; quality improvement; warfarin; ATRIAL-FIBRILLATION;
D O I
10.1097/JXX.0000000000000857
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background:Non-vitamin K antagonist oral anticoagulants (NOACs) are favorable in stroke prevention for geriatric patients with nonvalvular atrial fibrillation versus warfarin. These anticoagulants do not require international normalized ratio (INR) monitoring and have lower food/drug interactions. In addition, NOACs have risk reduction in bleeding and all-cause mortality compared with warfarin.Local problem:At a geriatric primary care practice, two registered nurses manage 88 patients on warfarin for INR monitoring. Nurse practitioners (NPs) provide oversight for warfarin titration after abnormal results. The goal of this quality-improvement project was to decrease the time spent monitoring patients on warfarin.Methods:Primary care providers and cardiologists of patients on warfarin were contacted to gain approval of transition to a NOAC. The NP reviewed patients' renal function and the indication for anticoagulation and then created a list of eligible patients for transition.Interventions:Patients eligible for transition to NOACs were contacted for their consent. The transition process included stopping warfarin, ordering apixaban, ordering INR level, educating about starting apixaban, and coordinating appropriate follow-up.Results:Of 88 patients on warfarin, 21 were eligible for conversion from warfarin to apixaban. Of these 21 patients, 66% (n = 14) consented to the conversion. Of those who were not converted to apixaban, five declined due to cost and two were lost to follow-up.Conclusion:There was a reduction in nurses' monthly monitoring of patients on warfarin by 22%. Transition to NOAC was not only beneficial for patient safety and efficacy but also reduced nursing clinical time for anticoagulation encounters.
引用
收藏
页码:380 / 385
页数:6
相关论文
共 50 条
  • [41] Comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in the elderly Asian patients with atrial fibrillation
    Chao, T. F.
    Liao, J. N.
    Lip, G. Y. H.
    Chen, S. A.
    EUROPEAN HEART JOURNAL, 2019, 40 : 2997 - 2997
  • [42] Intracerebral Hemorrhagic Expansion Occurs in Patients Using Non-Vitamin K Antagonist Oral Anticoagulants Comparable with Patients Using Warfarin
    Melmed, Kara R.
    Lyden, Patrick
    Gellada, Norman
    Moheet, Asma
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2017, 26 (08): : 1874 - 1882
  • [43] Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study
    Liu, Shin-Huei
    Chao, Tze-Fan
    Chan, Yi-Hsin
    Liao, Jo-Nan
    Chen, Tzeng-Ji
    Lip, Gregory Y. H.
    Chen, Shih-Ann
    EUROPACE, 2023, 25 (05):
  • [44] Inconclusive Findings in Non-Vitamin K Antagonist Oral Anticoagulants Study
    Khan, Faizan
    Lun, Ronda
    Hill, Michael D.
    JAMA INTERNAL MEDICINE, 2024, 184 (05) : 583 - 584
  • [45] Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
    Dincq, Anne-Sophie
    Lessire, Sarah
    Douxfils, Jonathan
    Dogne, Jean-Michel
    Gourdin, Maximilien
    Mullier, Francois
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [46] Non-Vitamin K Antagonist Oral Anticoagulants An Appeal for Consensus on Terminology
    Lip, Gregory Y. H.
    Camm, A. John
    Hylek, Elaine M.
    Halperin, Jonathan L.
    Weitz, Jeffrey I.
    CHEST, 2014, 145 (05) : 1177 - 1178
  • [47] Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation
    Fanaroff, Alexander C.
    Ohman, E. Magnus
    ANNUAL REVIEW OF MEDICINE, VOL 70, 2019, 70 : 61 - 75
  • [48] Misdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Primary Care
    Cardoso, Carlos Seica
    Sousa, Joao Andre
    Simoes, Pedro
    Silva, Beatriz
    Albuquerque, Ana
    Esperanca, Ana
    Cibrao, Ana
    Correia, Artur
    Goncalves, Joana
    Mortagua, Joana
    Almeida, Jose Eduardo
    Oliveira, Leonor
    Garcia, Jose
    Duarte, Mariana
    Loureiro, Mariana
    Costa e Silva, Marta
    Fraga, Marta
    Lopes, Paulo
    Brandao, Rui
    Miguel, Susana
    Queiros, Teresa
    Santo, Gustavo
    Silva, Fernando
    Sargento-Freitas, Joao
    CLINICAL THERAPEUTICS, 2020, 42 (06) : 1132 - +
  • [49] Safety of non-vitamin K antagonist oral anticoagulants - coronary risks
    Caldeira, Daniel
    Ferreira, Joaquim J.
    Pinto, Fausto J.
    Costa, Joao
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (06) : 731 - 740
  • [50] Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis
    Ghaffarpasand, Eiman
    Tehrani, Maneli D.
    Marszalek, Jolanta
    Chi, Gerald
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2018, 46 (03) : 332 - 338